|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.375 GBX | -4.44% |
|
-8.51% | -33.85% |
| Apr. 24 | Genedrive enters clinical trial deal in US for MT-RNR1 US approval | AN |
| Apr. 03 | FTSE 100 up thanks to US economic data | AN |
genedrive plc reported earnings results for the half year ended December 31, 2023. For the half year, the company reported sales was GBP 0.238 million compared to GBP 0.021 million a year ago. Net loss was GBP 2.04 million compared to GBP 2.19 million a year ago.
Basic loss per share from continuing operations was GBP 0.02 compared to GBP 0.024 a year ago. Diluted loss per share from continuing operations was GBP 0.02 compared to GBP 0.024 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -33.85% | 9.58M | |
| -12.91% | 19.08B | |
| -46.21% | 2.65B | |
| +18.15% | 1.87B | |
| -3.12% | 1.61B | |
| +23.78% | 1.21B | |
| -10.69% | 1.02B | |
| -20.89% | 905M | |
| -7.14% | 716M | |
| -18.10% | 682M |
GENEDRIVE PLC 
